KRAS mutations in pancreatic cancer: could we talk about a risk factor for the development of thromboembolic phenomena?
Rev. esp. enferm. dig
; 116(4): 236-237, 2024. tab
Article
en En
| IBECS
| ID: ibc-232480
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
The oncogenic KRAS mutation is associated with increased tissue factor expression and thus hypercoagulability. In this regard, numerous studies published in the last decade have shown that KRAS mutations are an important risk factor for the development of thromboembolic phenomena in neoplasms of the digestive tract, such as colorectal cancer. On the other hand, some recently published studies suggest that KRAS mutations are also associated with an increased risk of developing thromboembolic phenomena in pancreatic cancer. Based on these premises, we have conducted a single-centre retrospective study on a cohort of patients with pancreatic cancer. Our aim is to demonstrate whether there is an association between the presence of KRAS mutations in our cohort of pancreatic cancer patients and an increased risk of developing thromboembolic phenomena. (AU)
Palabras clave
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Neoplasias Pancreáticas
/
Trombosis
/
Embolia
Límite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Rev. esp. enferm. dig
Año:
2024
Tipo del documento:
Article